Fox Chase Cancer Center News

PHILADELPHIA (October 18, 2022)—The development of a family of drugs known as Bruton tyrosine kinase inhibitors (BTKi) was a huge step forward in treating chronic lymphocytic leukemia and non-Hodgkin lymphoma.

PHILADELPHIA (October 17, 2022)—Fox Chase Cancer Center was recently awarded a grant for $6 million over the course of five years to develop a new Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT). The new National Cancer Institute (NCI) program was created to establish a pipeline for the discovery of new cancer-prevention agents.

PHILADELPHIA (October 10, 2022)— Fox Chase Cancer Center is pleased to announce the hiring of Charnita Zeigler-Johnson, PhD, MPH, as Associate Director of Community Outreach and Engagement (COE).

PHILADELPHIA (October 6, 2022)—The Department of Medicine at Fox Chase Cancer Center is pleased to announce the hiring of Joseph R. Triggs, MD, PhD, as an assistant professor in the Division of Gastroenterology.

PHILADELPHIA (September 27, 2022)—Researchers at Fox Chase Cancer Center have identified a new cellular pathway that plays a key role in causing melanoma to become invasive and hastening its spread.

PHILADELPHIA (September 27, 2022)—In a recently published study, researchers at Fox Chase Cancer Center and Temple University found that only a few so called “leader cells” are necessary for metastasis of breast cancer—the spread of cancer cells from their point of origin to other parts of the body—to occur. The finding underscores the need for more personalized and targeted approaches to fighting cancer.

PHILADELPHIA (September 16, 2022)— The National Comprehensive Cancer Network^® (NCCN^®) hosted a policy summit to examine practice changes and trends in legislative and regulatory efforts that affect patient access to cancer screening and risk reduction.

PHILADELPHIA (September 15, 2022)—Researchers at Fox Chase Cancer Center have been awarded a three-year $250,000 grant to investigate methods of improving the cardiovascular management of patients with prostate cancer being treated with androgen deprivation therapy (ADT).